Pfizer allows Teva’s generic Viagra

Pfizer allows Teva’s generic Viagra
December 12, 2013
Life Sciences Intellectual Property Review

William C. Baton, a partner in the Life Sciences and Intellectual Property and Technology practices, was quoted about the settlement agreement that will allow Teva Pharmaceutical Industries to launch a generic version of Pfizer Ltd’s Viagra tablets in the U.S. market in December 2017. Teva will pay Pfizer a royalty for a license to produce the drug more than two years before the Viagra patent expires.

Bill said in the article that the settlement appears to a business decision on Pfizer’s part. “Perhaps Pfizer thinks it better to settle and have its opponent become someone that pays a royalty to them, as opposed to risking a decision of noninfringement or invalidity – in which case, they would have no way to negotiate anything further and would lose any share of exclusivity.”

Click here to read the story.